Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency-Reference-Cited by-同舟云学术

Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency

Published:2019-09-05 Issue:10 Volume:381 Page:933-944
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Grace Rachael F.¹,Rose Christian¹,Layton D. Mark¹,Galactéros Frédéric¹,Barcellini Wilma¹,Morton D. Holmes¹,van Beers Eduard J.¹,Yaish Hassan¹,Ravindranath Yaddanapudi¹,Kuo Kevin H.M.¹,Sheth Sujit¹,Kwiatkowski Janet L.¹,Barbier Ann J.¹,Bodie Susan¹,Silver Bruce¹,Hua Lei¹,Kung Charles¹,Hawkins Peter¹,Jouvin Marie-Hélène¹,Bowden Chris¹,Glader Bertil¹

Affiliation:

1. From the Dana–Farber/Boston Children’s Cancer and Blood Disorders Center and Harvard Medical School, Boston (R.F.G.), and Agios Pharmaceuticals, Cambridge (A.J.B., S.B., L.H., C.K., P.H., M.-H.J., C.B.) — all in Massachusetts; Hôpital Saint Vincent de Paul, Lille (C.R.), and Unité des Maladies Génétiques du Globule Rouge, Centre Hospitalier Universitaire Henri Mondor, Créteil (F.G.) — both in France; Hammersmith Hospital, Imperial College Healthcare NHS Trust, London (D.M.L.); Fondazione IRCCS Ca’ Granda...

Funder

Agios Pharmaceuticals, Inc.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1902678

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnosis and management of pyruvate kinase deficiency: international expert guidelines;The Lancet Haematology;2024-02

2. Pharmacological Profile of FDA-Approved Orphan Drugs in the Year 2022;Current Pharmacology Reports;2024-01-30

3. Red Blood Cells as Therapeutic Target to Treat Sickle Cell Disease;Antioxidants & Redox Signaling;2024-01-23

4. Regulation of tumor microenvironment by nutrient trafficking;Biomarkers in Cancer Detection and Monitoring of Therapeutics;2024

5. Neonatal Erythrocyte Disorders;Avery's Diseases of the Newborn;2024